2021
Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient
Jacobs JW, Gisriel SD, Iyer K, Rinder HM. Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient. Journal Of Thrombosis And Thrombolysis 2021, 53: 945-949. PMID: 34697688, PMCID: PMC8544916, DOI: 10.1007/s11239-021-02591-4.Peer-Reviewed Original ResearchConceptsPartial thromboplastin timeLupus anticoagulantFVIII inhibitorsAsymptomatic patientsFactor VIIIComprehensive hematologic evaluationLife-threatening hemorrhageTypical laboratory findingsDistinctive clinical presentationFactor VIII inhibitorsRisk of thrombosisSigns of hemorrhageSevere bleeding diathesisCoagulation factor VIIIImmunosuppressive therapyClinical presentationClinical symptomsPathologic antibodiesVIII inhibitorsLaboratory findingsHematologic evaluationUnique presentationBleeding diathesisThromboplastin timeAutoantibodies
1997
Acquired von Willebrand's disease: A concise review
Rinder M, Richard R, Rinder H. Acquired von Willebrand's disease: A concise review. American Journal Of Hematology 1997, 54: 139-145. PMID: 9034288, DOI: 10.1002/(sici)1096-8652(199702)54:2<139::aid-ajh7>3.0.co;2-y.Peer-Reviewed Original ResearchConceptsVon Willebrand factorHigh molecular weight multimersMonoclonal gammopathyAcquired von Willebrand diseaseEmergent cardiac surgeryUnderlying lymphoproliferative disorderLower functional levelUnderlying lymphoproliferative diseaseVon Willebrand diseaseIntravenous immunoglobulinCardiac surgeryLymphoproliferative disordersFactor inhibitorsAutoimmune diseasesLymphoproliferative diseaseUnderlying disorderEffective therapyBleeding diathesisIllustrative case historiesAvWDTherapeutic strategiesAntigenic levelsWillebrand diseaseReticuloendothelial systemTumor cells